Contineum Therapeutics has concluded the targeted enrolment of 168 subjects in its Phase II trial of M1 receptor antagonist ...

Subcutaneous ocrelizumab (SC OCR) was found to be safe for patients with relapsing and primary progressive multiple sclerosis ...

Background Treatment options for patients suffering from progressive forms of multiple sclerosis (MS) remain inadequate. Mast cells actively participate in the pathogenesis of MS, in part because ...

The treatment of multiple sclerosis (MS) has improved dramatically over the past two decades thanks to the advent of a second generation of immunomodulatory therapies. They have significantly ...

The researchers found that a biomarker in the blood called neurofilament light chain (NfL) increased after menopause. This ...

MS can cause a range of symptoms, including: There’s currently no cure for MS, but treatments such as disease-modifying therapies may help reduce the frequency and severity of MS relapses and ...

An investigational drug for multiple sclerosis from Io Therapeutics has restored leg mobility and myelin nerve coatings in ...

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...

Immunic Therapeutics says it's "on track" in its MS clinical trials of vidofludimus calcium, with CALLIPER top-line data ...

Combination therapy with modafinil and CBT was as effective as modafinil monotherapy or CBT alone in the treatment of MS-related fatigue at 12 weeks.

Oct. 17, 2024 — In a study of commonly used treatments for multiple sclerosis, both medical and behavioral interventions, and a combination of the two, resulted in ... New Study Finds a ...